AGAP2 and non-small cell lung carcinoma: Additionally, the authors mentioned that the combination of TBILA/AGAP2-AS1 with Cyfra21 (KRT19), a protein widely used in clinical practices, could distinguish all NSCLC patients from healthy controls in their study [247].